Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics

Uttpal Anand; Abhijit Dey; Arvind K. Singh Chandel; Rupa Sanyal; Amarnath Mishra; Devendra Kumar Pandey; Valentina De Falco; Arun Upadhyay; Ramesh Kandimalla; Anupama Chaudhary; Jaspreet Kaur Dhanjal; Saikat Dewanjee; Jayalakshmi Vallamkondu; José M. Pérez de la Lastra

doi:10.1016/j.gendis.2022.02.007

您当前的位置：

首页 >

文章列表页 >

Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics

Review article | 更新时间：2023-08-29

- Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics
- Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics
- Genes & Diseases 2023年10卷第4期
- 作者机构：
  
  1. Department of Physics, National Institute of Technology-Warangal, Warangal, Telangana,India,506004
  2. Orinin-BioSystems, LE-52, Lotus Road 4, CHD City, Karnal, Haryana,India,132001
  3. CSIR-Indian Institute of Chemical Technology,, Telangana,Hyderabad,India,500007
  4. Department of Biochemistry, School of Life Sciences, Central University of Rajasthan, Bandar Sindari, Kishangarh Ajmer, Rajasthan,India,305817
  5. Department of Biochemistry, Kakatiya Medical College, Warangal, Telangana,India,506007
  6. Faculty of Science and Technology, Amity Institute of Forensic Sciences, Amity University Uttar Pradesh, Noida,India,201313
  7. Institute of Endocrinology and Experimental Oncology (IEOS), National Research Council (CNR), Department of Molecular Medicine and Medical Biotechnology (DMMBM), University of Naples Federico II,Naples,Italy,80131
  8. Department of Computational Biology, Indraprastha Institute of Information Technology Delhi (IIIT-D), Okhla Industrial Estate, Phase III,New Delhi,India,110020
  9. Advanced Pharmacognosy Research Laboratory, Department of Pharmaceutical Technology, Jadavpur University, Kolkata,India,700032
  10. Biotechnology of Macromolecules Research Group, Instituto de Productos Naturales y Agrobiología, IPNA-CSIC, San Cristóbal de La Laguna 38206, Tenerife,Spain
  11. Center for Disease Biology and Integrative Medicine, Faculty of Medicine, The University of Tokyo,Tokyo,Japan,113-0033
  12. Department of Life Sciences, Ben-Gurion University of the Negev, Beer-Sheva,Israel,84105
  13. Department of Botany, Bhairab Ganguly College (affiliated to West Bengal State University), Kolkata, West Bengal,India,700056
  14. Department of Biotechnology, School of Bioengineering and Biosciences, Lovely Professional University, Phagwara, Punjab,India,144411
  15. Department of Life Sciences, Presidency University, Kolkata, West Bengal,India,700073
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2022.02.007
  中图分类号：
- 纸质出版日期：2023，
  
  网络出版日期：2023-7-1，
扫描看全文
Uttpal Anand, Abhijit Dey, Arvind K. Singh Chandel, 等. Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics[J]. Genes & Diseases, 2023,10(4).

Uttpal Anand, Abhijit Dey, Arvind K. Singh Chandel, et al. Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics[J]. Genes & Diseases, 2023,10(4).
Uttpal Anand, Abhijit Dey, Arvind K. Singh Chandel, 等. Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics[J]. Genes & Diseases, 2023,10(4). DOI： 10.1016/j.gendis.2022.02.007.

Uttpal Anand, Abhijit Dey, Arvind K. Singh Chandel, et al. Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics[J]. Genes & Diseases, 2023,10(4). DOI： 10.1016/j.gendis.2022.02.007.

摘要

Abstract

Cancer is an abnormal state of cells where they undergo uncontrolled proliferation and produce aggressive malignancies that causes millions of deaths every year. With the new understanding of the molecular mechanism(s) of disease progression

our knowledge about the disease is snowballing

leading to the evolution of many new therapeutic regimes and their successive trials. In the past few decades

various combinations of therapies have been proposed and are presently employed in the treatment of diverse cancers. Targeted drug therapy

immunotherapy

and personalized medicines are now largely being employed

which were not common a few years back. The field of cancer discoveries and therapeutics are evolving fast as cancer type-specific biomarkers are progressively being identified and several types of cancers are nowadays undergoing systematic therapies

extending patients' disease-free survival thereafter. Although growing evidence shows that a systematic and targeted approach could be the future of cancer medicine

chemotherapy remains a largely opted therapeutic option despite its known side effects on the patient's physical and psychological health. Chemotherapeutic agents/pharmaceuticals served a great purpose over the past few decades and have remained the frontline choice for advanced-stage malignancies where surgery and/or radiation therapy cannot be prescribed due to specific reasons. The present report succinctly reviews the existing and contemporary advancements in chemotherapy and assesses the status of the enrolled drugs/pharmaceuticals; it also comprehensively discusses the emerging role of specific/targeted therapeutic strategies that are presently being employed to achieve better clinical success/survival rate in cancer patients.

关键词

Keywords

Antimicrobial peptidesCancer therapiesClinical trialsCombination therapyImmunotherapyPatient survivalPersonalized medicineTargeted drug delivery

references

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

Molecular subtypes of colorectal cancer: An emerging therapeutic opportunity for personalized medicine

Cancer organoids: A platform in basic and translational research

Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy

Clinical applications of the CRISPR/Cas9 genome-editing system: Delivery options and challenges in precision medicine

The link between intracellular calcium signaling and exosomal PD-L1 in cancer progression and immunotherapy